| 1. |
- Bragina, O. D., et al.
(författare)
-
Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules : the first experience of clinical use
- 2021
-
Ingår i: Bûlleten' sibirskoj mediciny. - : Siberian State Medical University. - 1682-0363 .- 1819-3684. ; 20:1, s. 23-30
-
Tidskriftsartikel (refereegranskat)abstract
- Background. The main purpose of the Her2/neu status determination in clinical practice is to determine the indications for the appointment of targeted therapy. The main methods for detecting the Her2/neu status are the immunohistochemical method (IHC) and the fluorescence in situ hybridization (FISH); however, despite their widespread use, they have a number of significant disadvantages. Over the past few years, radionuclide diagnostics using a new class of alternative scaffold proteins that meet all the requirements for optimal delivery of radionuclides to tumor cells has become widespread.Aim. To study the possibility of clinical use of a radiopharmaceutical based on technetium-99m-labeled target molecules for the diagnosis of breast cancer with the Her2/neu overexpression in humans.Materials and methods. The study included 11 patients with breast cancer (T1–4N0–2M0) before systemic therapy: 5 with Her2/neu overexpression; expression of the marker was not detected in 6. In all cases, morphologicaland immunohistochemical studies were performed. In case of Her2/neu 2+, FISH analysis was performed. The radiopharmaceutical was prepared immediately before administration, after which it was slowly injected intravenously into the patient. Scintigraphic studies in the “WholeBody” mode and SPECT of the chest organs were performed 2, 4, 6 and 24 hours after injection.Results. Radiochemical yield, radiochemical purity and activity before administration were (80 ± 4)%, (98 ± 1)% and (434 ± 19.5) MBq, respectively. The greatest uptake by normal organs was observed at a time interval of 6 hours in the kidneys and at a moderate activity in the liver and lungs at the same time interval. The organ with the highest absorbed dose was the kidneys; significant accumulation was also detected in the adrenal glands, gallbladder, liver, pancreas and spleen. The smallest accu mulation of the studied drug was observed in the brain (0.001 ± 0.000) mGy and skin (0.001 ± 0.000) mGy. The effective dose was (0.009 ± 0.002) mGy. The difference between tumors with positive and negative Her2-neu expression was found at all time points. In this case, the best indicator was determined after 2 hours of drug injection (р < 0.05).Conclusion. Based on the results obtained, it can be indicated that the investigated radiopharmaceutical can be considered as a new additional method for the diagnosis of Her2-positive breast tumors.
|
|
| 2. |
- Ivanov, I. I., et al.
(författare)
-
Investigation of catalytic hydrogen sensors with platinum group catalysts
- 2021
-
Ingår i: Sensors and actuators. B, Chemical. - : Elsevier. - 0925-4005 .- 1873-3077. ; 346
-
Tidskriftsartikel (refereegranskat)abstract
- Environmental deterioration and limited resources of hydrocarbons push the development of alternative power sources. One of the most promising energy carriers is hydrogen. However, handling hydrogen is more hazardous than the use of hydrocarbons because it has a significantly wider flammable range. Thus the development of new sensors for preventing hydrogen leakage is the actual task of modern materials science and chemical engineering. In this work, the response of catalytic sensors to hydrogen with different catalysts of platinum group (Pt, Pd, Ir, Rh, Pt + Pd, Pt + Pd + Rh, Pt + Pd + Ir) in the pre-explosion concentration range is studied. Temperature dependencies of sensitivity are discussed. A hysteresis in sensor response is observed during the cycling of the supply voltage. This phenomenon can be explained by partial transformation of platinum group metal oxides into metallic phase at a temperature of more than 500 °C and reverse metal oxidation at temperatures less than 400 °C. It has been shown that the sensors with catalysts containing Ir and Rh demonstrate more preferable characteristics for practical applications. © 2021 Elsevier B.V.
|
|
| 3. |
- Revin, Leonid S., et al.
(författare)
-
Measurements of dichroic bow-tie antenna arrays with integrated cold-electron bolometers using YBCO oscillators
- 2024
-
Ingår i: Beilstein Journal of Nanotechnology. - 2190-4286. ; 15, s. 26-36
-
Tidskriftsartikel (refereegranskat)abstract
- We consider properties of dichroic antenna arrays on a silicon substrate with integrated cold-electron bolometers to detect radiation at frequencies of 210 and 240 GHz. This frequency range is widely used in cosmic microwave background experiments in space, balloon, and ground-based missions such as BICEP Array, LSPE, LiteBIRD, QUBIC, Simons Observatory, and AliCPT. As a direct radiation detector, we use cold-electron bolometers, which have high sensitivity and a wide operating frequency range, as well as immunity to spurious cosmic rays. Their other advantages are the compact size of the order of a few micrometers and the effect of direct electron cooling, which can improve sensitivity in typical closed-loop cycle 3He cryostats for space applications. We study a novel concept of cold-electron bolometers with two SIN tunnel junctions and one SN contact. The amplitude-frequency characteristics measured with YBCO Josephson Junction oscillators show narrow peaks at 205 GHz for the 210 GHz array and at 225 GHz for the 240 GHz array; the separation of these two frequency bands is clearly visible. The noise equivalent power level at an operating point in the current bias mode is 5 x 10-16 W/root Hz.
|
|
